QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ALKS

QT61Alkermes plc
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
44.99
+0.48+1.08%
OverviewShort InterestFilings
ALKSQT61Alkermes plc·NASDAQ
OverviewShort InterestFilings
44.99+1.08%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E48.44EPS (ttm)
0.90
Insider Own1.89%
Shs Outstand166.68M
Perf Week0.16%
Market Cap7.42BForward P/E82.81EPS next Y0.54Insider Trans0.25%Shs Float-Perf Month21.59%
Enterprise Value8.65BPEG-EPS next Q-0.04Inst Own-Short Float-Perf Quarter58.42%
Income152.83MP/S4.75EPS this Y-144.16%Inst Trans-Short Ratio-Perf Half Y60.33%
Sales1.56BP/B4.22EPS next Y236.70%ROA3.59%Short Interest-Perf YTD60.79%
Book/sh10.51P/C28.87EPS next 5Y-ROE8.82%52W High45.76 -1.68%Perf Year51.13%
Cash/sh3.07P/FCF33.45EPS past 3/5Y-ROIC3.89%52W Low25.17 78.74%Perf 3Y-
Dividend Est.-EV/EBITDA31.29Sales past 3/5Y9.90% 7.27%Gross Margin86.63%Volatility2.36% 2.60%Perf 5Y-
Dividend TTM-EV/Sales5.54EPS Y/Y TTM-56.22%Oper. Margin12.28%ATR (14)1.54Perf 10Y-
Dividend Ex-Date-Quick Ratio1.70Sales Y/Y TTM0.32%Profit Margin9.78%RSI (14)71.03Recom2.14
Dividend Gr. 3/5Y-Current Ratio2.27EPS Q/Q-407.69%SMA206.92%Beta0.87Target Price49.50
Payout0.00%Debt/Eq0.90Sales Q/Q28.01%SMA5018.88%Rel Volume3.69Prev Close44.51
Employees1,800LT Debt/Eq0.03EarningsJul 28SMA20039.82%Avg Volume2.09MPrice44.99
IPO DateJul 16, 1991Option/ShortYes / YesEPS/Sales Surpr.29.82% 8.26%Net Debt/EBITDA4.45Volume7,727,743Change1.08%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-18-26ReiteratedNeedhamBuy$50 → $54
Jun-09-26ReiteratedRBC CapitalOutperform$47 → $56
May-06-26ReiteratedNeedhamBuy$43 → $50
Feb-26-26ReiteratedH.C. WainwrightNeutral$46 → $43
Feb-23-26InitiatedWolfe ResearchOutperform$45
Oct-28-25ReiteratedJefferiesBuy$50 → $56
Oct-27-25ReiteratedMizuho Securities$40 → $45
Oct-23-25ReiteratedPiper SandlerOverweight$37 → $45
Sep-26-25UpgradeRBC CapitalSector Perform → Outperform$44
Sep-09-25ReiteratedNeedhamBuy$45 → $43
Latest News
Jun-17-26
Jun-17-2604:19PM
Alkermes Reports Phase 2 Vibrance‑2 Data; Says Alixorexton Trial In Narcolepsy Type 2 Meets Dual Primary Endpoints, Showing Sustained Wakefulness GainsBenzinga
Jun-15-26
Jun-15-2607:17AM
Venu Holding Pursues $80M Sale-Leaseback Transaction On Parking Garage Asset At Sunset Amphitheater In McKinney, TexasBenzinga
07:16AM
Alkermes Drug Gets Orphan Status in US and Europe, Wins Rare Disease Designations for AlixorextonBenzinga
Jun-10-26
Jun-10-2606:08PM
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition NearsYahoo
12:32PM
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,5631,4761,558
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A209196245
Gross Profit1,3531,2791,312
Selling, General and Administrative Excl. Other795702645
Research and Development355324245
Other Operating Expense12-12
Operating Income192254421
Interest Expense331223
Unusual Expense
———
Non-Operating Income (Expense)-46-50-46
Net Income Before Taxes204291444
Income Taxes525072
Consolidated Net Income153242367
Net Income From Continuing Operations153242372
Net Income153242367
EPS (Recurring)0.931.472.22
EPS (Basic, Before Extraordinaries)0.931.472.22
EPS (Diluted)0.901.432.17
EBITDA277331495
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio49.9919.57—
Price To Sales Ratio4.783.13—
Gross Margin86.5686.6584.21
Operating Margin12.2817.2127.02
Net Margin9.7916.4023.56
Shares Outstanding166165165
Market Capitalization7,4684,617—
Operating Lease Expense
———
Insider Trading Volume
$48.36$42.80$37.23$31.67$26.11● Close Price0.00M0.61M1.21M1.82M2.42MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Wright Christopher IDirectorJun 12 '26Sale45.102,00090,20025,680Jun 12 12:00 AM
Gaffin David JosephEVP, CLO, Alkermes, Inc.Jun 04 '26Sale43.052,03487,564229,524Jun 04 12:00 AM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 01 '26Option Exercise19.3410,000193,40086,389Jun 01 12:00 AM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 01 '26Sale41.679,000375,04477,389Jun 01 12:00 AM
Parisi Samuel JosephVP, Finance (Interim PAO)May 29 '26Sale42.3616,217687,0077,717May 29 12:00 AM
Parisi Samuel JosephVP, Finance (Interim PAO)May 29 '26Option Exercise19.4832,434631,95623,934May 29 12:00 AM
snyderman nancy lynn MDDirectorMay 21 '26Option Exercise0.0012,284016,870May 22 12:00 AM
Lurker NancyDirectorMay 21 '26Option Exercise0.0012,284019,697May 22 12:00 AM
Wright Christopher IDirectorMay 21 '26Option Exercise0.0012,284029,155May 22 12:00 AM
Wilson Frank AndersDirectorMay 21 '26Option Exercise0.0012,284037,226May 22 12:00 AM
MCKEON BRIAN PDirectorMay 21 '26Option Exercise0.0012,284040,011May 22 12:00 AM
LAURENCIN CATO TDirectorMay 21 '26Option Exercise0.0012,284035,244May 22 12:00 AM
GAYNOR RICHARDDirectorMay 21 '26Option Exercise0.0012,284037,226May 22 12:00 AM
Cooke ShaneDirectorMay 21 '26Option Exercise0.0012,2840109,886May 22 12:00 AM
Gaffin David JosephEVP, CLO, Alkermes, Inc.May 04 '26Sale33.202,03467,529231,558May 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR